Halozyme Therapeutic (HALO) 9.80 $HALO Halozyme

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Halozyme Therapeutic (HALO) 9.80 $HALO

Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
PR Newswire - Wed Aug 31, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Wells Fargo Healthcare Conference in Boston on Weds., Sept. 7 at 4:05 p.m. ET/1:05 p.m. PT. and at the Baird Global Healthcare Conference in New York on Thurs., Sept. 8 at 1:25 p.m. ET/10:25 a.m. PT. Dr. Helen Torley, president and CEO, will represent the company at both conferences.
HALO: 9.80 (-0.08), WFC: 50.80 (+0.18)

Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix
PR Newswire - Tue Aug 23, 6:40AM CDT
Biotechnology harnesses cellular and biomolecular processes to develop technologies and products, which include food technology, genetic research, healthcare, and environmental technology. Equities under assessment on Stock-Callers.com today are: Halozyme Therapeutics Inc. (NASDAQ: HALO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Chimerix Inc. (NASDAQ: CMRX). These stocks research reports can be downloaded now by simply registering for free at:
HALO: 9.80 (-0.08), CMRX: 4.81 (+0.23), ACHN: 8.26 (-0.10), AEGR: 1.63 (+0.01)

Halozyme Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the second quarter ended June 30.
HALO: 9.80 (-0.08)

Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
PR Newswire - Wed Jun 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into an agreement with Oxford Finance LLC and Silicon Valley Bank to refinance its existing senior secured loan facility.
HALO: 9.80 (-0.08)

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
PR Newswire - Sat Jun 04, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).
HALO: 9.80 (-0.08)

Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
PR Newswire - Tue May 17, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial officer, will provide a corporate overview.
HALO: 9.80 (-0.08)

Halozyme Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 3:37PM CDT
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $19.8 million in its first quarter.
HALO: 9.80 (-0.08)

Halozyme Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, which included an increase in revenue of 128 percent from the prior-year period and a net loss of $19.8 million, or $0.16 per share, compared to a net loss in the first quarter of 2015 of $15.1 million, or $0.12 per share.
HALO: 9.80 (-0.08)

The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
Zacks Equity Research - Zacks Investment Research - Mon May 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
HALO: 9.80 (-0.08), KITE: 57.62 (-1.09), INCY: 81.10 (+0.12), HZNP: 18.80 (-0.21), JUNO: 29.58 (-1.95)

Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 9.80 (-0.08), KITE: 57.62 (-1.09), MDCO: 39.17 (-0.97), INCY: 81.10 (+0.12), HZNP: 18.80 (-0.21), AMGN: 170.06 (-0.70), JUNO: 29.58 (-1.95)

Halozyme Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (HALO)
Comtex SmarTrend(R) - Fri Apr 22, 1:01PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 2 months, Halozyme Therapeutics has returned 31.11% as of today's recent price of $11.89.
HALO: 9.80 (-0.08)

Halozyme to Host First Quarter 2016 Financial Results Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2016.
HALO: 9.80 (-0.08)

Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
PR Newswire - Mon Apr 18, 3:01PM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR).
HALO: 9.80 (-0.08)

Halozyme Therapeutics Up 21.8% Since SmarTrend Uptrend Call (HALO)
Comtex SmarTrend(R) - Thu Apr 07, 1:55PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 1 month, Halozyme Therapeutics has returned 21.79% as of today's recent price of $11.04.
HALO: 9.80 (-0.08)

Global Halozyme Therapeutics, Inc. Market Business Survey Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'HALOZYME THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the HALOZYME THERAPEUTICS, INC.'s pharmaceutical research and development focus.
HALO: 9.80 (-0.08)

Shares of HALO Down 39.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 02, 5:58PM CST
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on January 11th, 2016 at $13.39. In approximately 3 weeks, Halozyme Therapeutics has returned 39.41% as of today's recent price of $8.11.
HALO: 9.80 (-0.08)

Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call
PR Newswire - Mon Feb 01, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on Monday, February 29 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2015.
HALO: 9.80 (-0.08)

Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing
PR Newswire - Tue Jan 26, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE(TM) products, received only from Halozyme's collaborations with Roche and Baxalta.
HALO: 9.80 (-0.08)

Halozyme Therapeutics Shares Down 29.9% Since SmarTrend's Sell Call (HALO)
Comtex SmarTrend(R) - Tue Jan 26, 1:03PM CST
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on January 11th, 2016 at $13.39. In approximately 2 weeks, Halozyme Therapeutics has returned 29.92% as of today's recent price of $9.38.
HALO: 9.80 (-0.08)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 306

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 0

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Cordance Medical Secures $8M Seed Funding for Brain Solutions

Updated Category News Views 235

Groundbreaking Seed Financing for Cordance Medical Cordance Medical, a leader in noninvasive focused ultrasound technology for treating brain diseases, has successfully completed an oversubscribed seed financing round. This milestone was highlighted by exceeding the initial $8 million target, with participation from both new and existing investors such as Shanda Grab...

Continue Reading
Man Group PLC Discloses Open Positions for Aviva PLC

Updated Category News Views 179

Man Group PLC Reports on Relevant Securities In a significant disclosure, Man Group PLC has announced its public opening position in relation to Aviva PLC, emphasizing transparency in its dealings concerning relevant securities. The regulations governing such disclosures necessitate comprehensive reporting, particularly when interests exceed 1% of the relevant securities....

Continue Reading
Baird Raises Griffon Corp Price Target to $92, Outperform Rating

Updated Category News Views 63

Baird Updates Griffon Corp's Stock Projection Baird has elevated its price target on shares of Griffon Corp (NYSE: GFF) from $84.00 to $92.00. This revision to the target price comes with a maintained Outperform rating, signaling strong confidence in the company's outlook. The analyst from Baird forecasts a gradual increase in Griffon's fiscal fourth-quarter financial...

Continue Reading
Experience SoCal Car Culture at SPARQ's LA Auto Show Exhibit

Updated Category News Views 316

SPARQ Returns to LA Auto Show with Exciting Exhibit California's automotive AI startup SPARQ is making waves by returning to the highly anticipated Los Angeles Auto Show this November. This year, visitors can expect an immersive experience inside the Concourse Hall, showcasing an impressive lineup of hypercars, Formula 1 vehicles, and famous cars from iconic films such as...

Continue Reading
Sagent Behavioral Health: A New Era for Mental Wellness Providers

Updated Category News Views 616

Sagent Behavioral Health: Transforming Behavioral Healthcare Sagent Behavioral Health marks a significant advancement in the provision of mental health services in the Midwest. With the consolidation of Nystrom & Associates and its affiliated brands, including Ellie Mental Health, LifeWorks, and several others, this new entity aims to create a unified and robust network...

Continue Reading